These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 25428235)

  • 21. Inhibition of the renin angiotensin aldosterone system: focus on aliskiren.
    Rao MS
    J Assoc Physicians India; 2010 Feb; 58():102-8. PubMed ID: 20653151
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Does concurrent renin-angiotensin-aldosterone blockade in (older) chronic kidney disease patients play a role in the acute renal failure epidemic in US hospitalized patients?--Three cases of severe acute renal failure encountered in a northwestern Wisconsin Nephrology practice.
    Onuigbo MA
    Hemodial Int; 2009 Oct; 13 Suppl 1():S24-9. PubMed ID: 19775421
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors.
    Weir MR; Rolfe M
    Clin J Am Soc Nephrol; 2010 Mar; 5(3):531-48. PubMed ID: 20150448
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of RAAS Inhibitors in Patients with Kidney Disease.
    Zhang F; Liu H; Liu D; Liu Y; Li H; Tan X; Liu F; Peng Y; Zhang H
    Curr Hypertens Rep; 2017 Aug; 19(9):72. PubMed ID: 28791529
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Renin-angiotensin-aldosterone system inhibitors in heart failure.
    Shearer F; Lang CC; Struthers AD
    Clin Pharmacol Ther; 2013 Oct; 94(4):459-67. PubMed ID: 23852393
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of withdrawing vs continuing renin-angiotensin blockers on incidence of acute kidney injury in patients with renal insufficiency undergoing cardiac catheterization: Results from the Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker and Contrast Induced Nephropathy in Patients Receiving Cardiac Catheterization (CAPTAIN) trial.
    Bainey KR; Rahim S; Etherington K; Rokoss ML; Natarajan MK; Velianou JL; Brons S; Mehta SR;
    Am Heart J; 2015 Jul; 170(1):110-6. PubMed ID: 26093871
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The evolving landscape of RAAS inhibition: from ACE inhibitors to ARBs, to DRIs and beyond.
    Epstein BJ; Leonard PT; Shah NK
    Expert Rev Cardiovasc Ther; 2012 Jun; 10(6):713-25. PubMed ID: 22894628
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dual blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy: the role of aldosterone.
    Schjoedt KJ; Jacobsen P; Rossing K; Boomsma F; Parving HH
    Horm Metab Res; 2005 Apr; 37 Suppl 1():4-8. PubMed ID: 15918104
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
    Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [How I treat... by optimizing the blockade of the renin-angiotensin-aldosterone system].
    Schleich F; Krzesinski JM; Piérard L; Scheen AJ
    Rev Med Liege; 2008 Apr; 63(4):174-81. PubMed ID: 18575070
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of renin-angiotensin-aldosterone system-blocking drugs on peritoneal membrane in peritoneal dialysis patients.
    Trošt Rupnik A; Pajek J; Guček A; Osredkar J; Kovač D; Bren A; Klančič D; Saksida S; Rus I; Globokar M; Drozg A; Lešnik M; Plešivčnik Z; Ekart R; Lopert S; Lindič J
    Ther Apher Dial; 2013 Aug; 17(4):425-30. PubMed ID: 23931884
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Renal safety and angiotensin II blockade medications in patients undergoing non-emergent coronary angiography: a randomized controlled study.
    Wolak T; Aliev E; Rogachev B; Baumfeld Y; Cafri C; Abu-Shakra M; Novack V
    Isr Med Assoc J; 2013 Nov; 15(11):682-7. PubMed ID: 24511648
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Meta-analysis of effect of renin-angiotensin-aldosterone system blockers on contrast-induced nephropathy.
    Wang W; Qu W; Sun D; Liu X
    J Renin Angiotensin Aldosterone Syst; 2020; 21(2):1470320320919587. PubMed ID: 32370685
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Renin-angiotensin-aldosterone system blockade effects on the kidney in the elderly: benefits and limitations.
    Turgut F; Balogun RA; Abdel-Rahman EM
    Clin J Am Soc Nephrol; 2010 Jul; 5(7):1330-9. PubMed ID: 20498247
    [TBL] [Abstract][Full Text] [Related]  

  • 35. RAAS inhibition and the course of Alport syndrome.
    Savva I; Pierides A; Deltas C
    Pharmacol Res; 2016 May; 107():205-210. PubMed ID: 26995302
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Renin-angiotensin-aldosterone system blockade in high-risk hypertensive patients: current approaches and future trends.
    Gullapalli N; Bloch MJ; Basile J
    Ther Adv Cardiovasc Dis; 2010 Dec; 4(6):359-73. PubMed ID: 20965951
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of dual RAAS blockade and higher-dose RAAS inhibition on nephropathy progression.
    Bakris GL; Weir MR
    Postgrad Med; 2008 Apr; 120(1):33-42. PubMed ID: 18467807
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis.
    Sarafidis PA; Stafylas PC; Kanaki AI; Lasaridis AN
    Am J Hypertens; 2008 Aug; 21(8):922-9. PubMed ID: 18535536
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute kidney injury and death associated with renin angiotensin system blockade in cardiothoracic surgery: a meta-analysis of observational studies.
    Yacoub R; Patel N; Lohr JW; Rajagopalan S; Nader N; Arora P
    Am J Kidney Dis; 2013 Dec; 62(6):1077-86. PubMed ID: 23791246
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is angiotensin-converting enzyme inhibitor a contraindication for contrast-induced nephropathy prophylaxis? A review about its paradox.
    Li X; Li T; Cong H
    Cardiovasc Ther; 2012 Oct; 30(5):273-6. PubMed ID: 21884031
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.